脑栓塞保护装置的地理区域差异:PROTECTED TAVR随机临床试验的事后分析
该研究为PROTECTED TAVR随机试验的事后分析,纳入3000例经股动脉TAVR患者,比较使用与不使用Sentinel脑栓塞保护装置(CEP)的卒中结局。主试验未显示CEP显著降低围术期卒中且无区域交互作用;本事后分析中,美国队列使用CEP者总体卒中相对风险降低50%、致残性卒中降低73%,而美国以外队列未观察到治疗效应。
要点
- 主试验中CEP对72小时内或出院前卒中发生率无显著影响,且无地理区域交互作用。
- 美国队列使用CEP者总体卒中相对风险降低50%,致残性卒中相对风险降低73%。
- 美国以外队列未观察到CEP对卒中风险降低的治疗效应。
核心结论
- PROTECTED TAVR试验未能显示CEP对TAVR围术期卒中发生率有显著影响。
- 尽管无显著区域交互作用,该探索性事后分析提示美国队列有更大卒中降低趋势,而美国以外队列无此趋势。
- 这些发现为假设生成性,需进一步研究患者特征或操作实践的区域差异是否影响CEP疗效。
研究设计与样本
- PROTECTED TAVR为前瞻性、上市后随机临床试验的事后分析,于2020年2月至2022年1月在美国、欧洲和澳大利亚的51家医院开展。
- 纳入症状性主动脉瓣狭窄接受经股动脉TAVR的患者,随机按中心、手术风险和预定TAVR瓣膜类型分层。
- 排除左侧颈总动脉或头臂动脉狭窄大于70%或解剖条件妨碍CEP装置放置的患者。
- 共纳入并随机化3000例患者(1803例[60.1%]男性;平均[SD]年龄78.9[7.8]岁);美国队列1833例(单纯TAVR 919例,TAVR+CEP 914例),美国以外队列1167例(单纯TAVR 580例,TAVR+CEP 587例)。
主要发现
- 美国队列患者较美国以外队列更年轻、男性比例更高、心房颤动患病率更低、二叶式主动脉瓣及糖尿病和外周血管疾病患病率更高。
- 主试验中,CEP组与对照组在TAVR后72小时内或出院前卒中发生率无显著差异,且无地理区域交互作用。
- 事后分析中,美国队列接受CEP治疗者较单纯TAVR者总体卒中相对风险降低50%,致残性卒中相对风险降低73%。
- 美国以外队列未观察到CEP对卒中风险降低的治疗效应。
临床怎么用
- 目前证据不支持常规使用CEP以显著降低TAVR围术期卒中,临床决策需个体化。
- 美国队列中观察到的卒中风险降低趋势提示需进一步研究区域差异对CEP疗效的影响。
局限性
- 本研究为事后探索性分析,结果属假设生成性,不能作为确切疗效证据。
- 原文未报告事后分析中区域差异的交互作用P值及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transcatheter aortic valve replacement (TAVR) is an established treatment option for many patients with severe symptomatic aortic stenosis; however, debris dislodged during the procedure can cause embolic stroke. The Sentinel cerebral embolic protection (CEP) device is approved for capture and removal of embolic material during TAVR but its efficacy has been debated. OBJECTIVE: To explore regional differences in the association of CEP utilization with stroke outcomes in patients undergoing TAVR. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a prospective, postmarket, randomized clinical trial evaluating TAVR performed with or without the CEP took place at 51 hospitals in the US, Europe, and Australia from February 2020 to January 2022. Patients with symptomatic aortic stenosis treated with transfemoral TAVR were included. Randomization was stratified according to center, operative risk, and intended TAVR valve type. Patients were excluded if the left common carotid or brachiocephalic artery had greater than 70% stenosis or if the anatomy precluded placement of the CEP device. Data for this post hoc study were analyzed from August to October 2024. INTERVENTION: TAVR with or without CEP. MAIN OUTCOMES AND MEASURES: The primary end point was the rate of all stroke events at hospital discharge or 72 hours post-TAVR, whichever came first. Neurological examinations were performed at baseline and postprocedure to identify stroke, disabling stroke, and other neurological outcomes. RESULTS: The Stroke Protection With Sentinel During Transcatheter Aortic Valve Replacement (PROTECTED TAVR) trial enrolled and randomized 3000 patients (1803 [60.1%] male; mean [SD] age, 78.9 [7.8] years): 1833 in the US cohort (TAVR alone: 919, TAVR with CEP: 914) and 1167 patients in the outside the US (OUS) cohort (TAVR alone: 580, TAVR with CEP: 587). Patients in the US cohort were younger, more predominantly male, had a lower prevalence of atrial fibrillation, and had a higher prevalence of bicuspid aortic valve, diabetes, and peripheral vascular disease compared with the OUS cohort. In the main trial, the incidence of stroke within 72 hours after TAVR or before discharge did not differ significantly between the CEP group and the control group, and there was no interaction by geographic region. In this post hoc analysis, patients treated with CEP in the US cohort exhibited a 50% relative risk reduction for overall stroke and a 73% relative risk reduction for disabling stroke compared to TAVR alone; a treatment effect on stroke risk reduction was not observed in the OUS cohort. CONCLUSION AND RELEVANCE: The PROTECTED TAVR trial could not show that the use of CEP had a significant effect on the incidence of periprocedural stroke during TAVR. Although there was no significant interaction by geographic region, this exploratory post hoc analysis suggests a trend toward greater stroke reduction in the US cohort but not in the OUS cohort. These findings are hypothesis generating, and further research is needed to determine if regional differences in patient characteristics or procedural practices affect CEP efficacy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04149535.
引用
- Makkar RR, Gupta A, Waggoner TE, et al. Cerebral Embolic Protection by Geographic Region: A Post Hoc Analysis of the PROTECTED TAVR Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 39471309. doi:10.1001/jamacardio.2024.4278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。